Standard concentration: 0.5 mg/mL This is a common concentration used by many compounding pharmacies
The effective date of this policy is January 1, 2026
Detection and in vitro metabolism of the confiscated peptides bpc 157 and mgf r23h
These changes are sustained during lactation

decreased TSH, decreased Total T4, and decreased Free T4) Uncommon (0.1% to 1%): Galactorrhea, hypoadrenalism, diabetes insipidus [Ref] Local Very common (10% or more): Injection site pain (13.8%), injection site reactions Common (1% to 10%): Injection site hematoma [Ref] Dermatologic Very common (10% or more): Alopecia (13.2%) Common (1% to 10%): Pruritus, bruise, rash Uncommon (0.1% to 1%): Cellulitis, petechiae, urticaria, basal cell carcinoma [Ref] Musculoskeletal Common (1% to 10%): Joint pain, backache Uncommon (0.1% to 1%): Arthritis, joint effusion, muscle pain, Raynaud's phenomenon [Ref] Psychiatric Common (1% to 10%): Depression Uncommon (0.1% to 1%): Anxiety, paranoia, libido decrease [Ref] Other Very common (10% or more): Fatigue (31.8%), generalized pain (15%) Common (1% to 10%): Weakness Uncommon (0.1% to 1%): Hearing loss, otitis [Ref] Respiratory Very common (10% or more): Upper respiratory tract infection (18.2%), sinusitis (12%) Common (1% to 10%): Cold symptoms, flu symptoms, epistaxis Uncommon (0.1% to 1%): Pneumonia, pulmonary nodule, status asthmaticus [Ref] Renal Uncommon (0.1% to 1%): Increased creatinine kinase [Ref] Hypersensitivity Uncommon (0.1% to 1%): Allergic reaction Frequency not reported : Anaphylactic reaction [Ref] Immunologic Very common (10% or more): Antibodies to octreotide (25%) Ocular Common (1% to 10%): Blurred vision, visual disturbance Uncommon (0.1% to 1%): Increased intraocular pressure [Ref] Genitourinary Common (1% to 10%): Urinary tract infection, pollakiuria Uncommon (0.1% to 1%): Gynecomastia, amenorrhea, polymenorrhea, oligomenorrhea, vaginitis, nephrolithiasis, hematuria [Ref] References 1

Rushing the titration rarely produces better results